Home › For Investigators › I-SPY Resources
Reviews & Editorials on I-SPY 2
Reinventing clinical trials
Laura Esserman’s 2015 lecture at ‘Exponential Medicine’ discussed the re-engineering of clinical trials, inspired by the insights of late Intel CEO Andy Grove into the differences between development in the semiconductor industry and healthcare.
Length: 26:50 min
I-SPY 2 and other platform trials
I-SPY2 Principal Statistician Don Berry of Berry Consultants explains the history and fundamentals of platform trial models and how they are changing drug development in breast cancer and beyond.
Length: 31:52 min
I-SPY Clinical Trials:
An interview with Dr. Laura Esserman
The ground-breaking I-SPY 2 trial of neoadjuvant treatment for locally advanced breast cancer established a new benchmark for efficiency of phase II clinical trials. Widely regarded as a pioneer of the ‘platform’ trial, I-SPY 2’s success continues to be a major influence on the development of next-generation trial designs in oncology and beyond.
Changing strategies in the 'war on cancer'
Dr. Angela DiMichele, Professor of Medicine and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania and I-SPY 2 Site Operations Working Group Chair discusses the innovations of I-SPY 2 and testing of new antibody-drug conjugates.
Length: 34:32 min
How to design an adaptive trial - Lessons learned, so far
How do you design an adaptive trial? Scott Berry one of the adaptive trial experts at Berry Consultants presents a recipe for designing a high-impact adaptive trial, secret sauce included.
Length: 38:18 min